Literature DB >> 32808728

ACTA2-AS1 suppresses lung adenocarcinoma progression via sequestering miR-378a-3p and miR-4428 to elevate SOX7 expression.

Kangtai Ying1, Ling Wang2, Guangyan Long3, Chan Lian1, Zhe Chen1, Wei Lin1.   

Abstract

Lung adenocarcinoma (LUAD) is the most common histological subtype of lung cancer. The abnormal expression of long noncoding RNAs (lncRNAs) can facilitate or suppress the development of malignant tumors. lncRNA actin alpha 2, smooth muscle antisense RNA 1 (ACTA2-AS1) has been reported to function as a tumor suppressor in liver cancer, nevertheless, its influences on LUAD remain to be investigated. In this paper, ACTA2-AS1 was identified as a downregulated lncRNA in LUAD samples and cells. Functionally, ACTA2-AS1 overexpression restrained cell proliferation but accelerated cell apoptosis in LUAD. In addition, we determined the suppressive effect of ACTA2-AS1 on LUAD cell invasion, migration, and epithelial-mesenchymal transition progress. Mechanistically, ACTA2-AS1 exert functions as a competing endogenous RNA through serving as a sponge for microRNA-378a-3p (miR-378a-3p) and microRNA-4428 (miR-4428) to elevate SRY-related high-mobility group box 7 (SOX7) expression. Importantly, SOX7 silencing could recover the ACTA2-AS1-mediated cell functions. To summarize, ACTA2-AS1 suppresses the malignant processes of LUAD cells through sequestering miR-378a-3p and miR-4428 to augment SOX7 expression.
© 2020 International Federation of Cell Biology.

Entities:  

Keywords:  ACTA2-AS1; SOX7; lung adenocarcinoma; miR-378a-3p; miR-4428

Mesh:

Substances:

Year:  2020        PMID: 32808728     DOI: 10.1002/cbin.11451

Source DB:  PubMed          Journal:  Cell Biol Int        ISSN: 1065-6995            Impact factor:   3.612


  7 in total

1.  Construction and Verification of a Hypoxia-Related 4-lncRNA Model for Prediction of Breast Cancer.

Authors:  Ye Zhao; Lixiao Liu; Jinduo Zhao; Xuedan Du; Qiongjie Yu; Jinting Wu; Bin Wang; Rongying Ou
Journal:  Int J Gen Med       Date:  2021-08-17

2.  Long non-coding RNA ACTA2-AS1 inhibits the cisplatin resistance of non-small cell lung cancer cells through inhibiting autophagy by suppressing TSC2.

Authors:  XueHui Liu; XuFeng Zhang; ShuZhang Du
Journal:  Cell Cycle       Date:  2022-01-05       Impact factor: 4.534

3.  Pan-Cancer Methylated Dysregulation of Long Non-coding RNAs Reveals Epigenetic Biomarkers.

Authors:  Ning Zhao; Maozu Guo; Chunlong Zhang; Chunyu Wang; Kuanquan Wang
Journal:  Front Cell Dev Biol       Date:  2022-05-27

4.  Integrated Dissection of lncRNA-miRNA-mRNA Pairs and Potential Regulatory Role of lncRNA PCAT19 in Lung Adenocarcinoma.

Authors:  Xiaomei Tang; Xiaoyan Hua; Xujin Peng; Yongyan Pei; Zhigang Chen
Journal:  Front Genet       Date:  2022-01-12       Impact factor: 4.599

5.  lncRNA ACTA2-AS1 predicts malignancy and poor prognosis of triple-negative breast cancer and regulates tumor progression via modulating miR-532-5p.

Authors:  Yi Peng; Xiaoxi Huang; Hongmei Wang
Journal:  BMC Mol Cell Biol       Date:  2022-07-27

6.  lncRNA ACTA2-AS1 inhibits malignant phenotypes of gastric cancer cells.

Authors:  Zhiping Liu; Kaibing Hu; Xiang Wang; Youqian Zhang; Weiping Wang; Yindi Wu
Journal:  Open Med (Wars)       Date:  2022-02-15

7.  Long Non-Coding RNAs Might Regulate Phenotypic Switch of Vascular Smooth Muscle Cells Acting as ceRNA: Implications for In-Stent Restenosis.

Authors:  Alberto Arencibia; Fernando Lanas; Luis A Salazar
Journal:  Int J Mol Sci       Date:  2022-03-12       Impact factor: 5.923

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.